Impact of interferon-alpha treatment on liver fibrosis in patients with chronic hepatitis B: An overview of published trials

Gastroenterologie Clinique et Biologique

Volumn 33, Issue 10-11, 2009, Pages 916-922

  Poynard, T ^a   Massard, J ^a   Rudler, M ^a   Varaud, A ^a   Lebray, P ^a   Moussalli, J ^a   Munteanu, M ^b   Ngo, Y ^b   Thabut, D ^a   Benhamou, Y ^a   Ratziu, V ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b BioPredictive ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; ENTECAVIR; INTERFERON; LAMIVUDINE; PEGINTERFERON; PEGINTERFERON ALPHA; PLACEBO; TENOFOVIR;

CLINICAL TRIAL; DISEASE COURSE; DISEASE MARKER; EVIDENCE BASED MEDICINE; HEPATITIS B; HUMAN; LIVER CIRRHOSIS; LIVER FIBROSIS; META ANALYSIS; METHODOLOGY; MONOTHERAPY; NONHUMAN; RISK BENEFIT ANALYSIS; RISK REDUCTION; SHORT SURVEY; SYSTEMATIC REVIEW; TREATMENT DURATION;

ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; LIVER CIRRHOSIS;

EID: 70350431469     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gcb.2009.06.006     Document Type: Short Survey

References (36)

1. Lai C.L., Ratziu V., Yuen M.F., and Poynard T. Viral hepatitis B. Lancet 362 (2003) 2089-2094
2. Poynard T., Mathurin P., Lai C.L., Guyader D., Poupon R., Tainturier M.H., et al. A comparison of fibrosis progression in chronic liver diseases. J Hepatol 38 (2003) 257-265
3. Hintze JL. NCSS 2007 User Guide. Kaysville Utah: Number Cruncher Statistical Systems software NCSS. 2007; pp. 200.
4. Carreño V., Marcellin P., Hadziyannis S., Salmerón J., Diago M., Kitis G.E., et al. Retreatment of chronic hepatitis B e antigen-positive patients with recombinant interferon alfa-2a. The European Concerted Action on Viral Hepatitis (EUROHEP). Hepatology 30 (1999) 277-282
5. Krogsgaard K. The long-term effect of treatment with interferon-alpha 2a in chronic hepatitis B. The long-term follow-up investigator group. The European Study Group on Viral Hepatitis (EUROHEP). Executive team on anti-viral treatment. J Viral Hepat 5 (1998) 389-397
6. Mazzella G., Saracco G., Festi D., Rosina F., Marchetto S., Jaboli F., et al. Long-term results with interferon therapy in chronic type B hepatitis: a prospective randomized trial. Am J Gastroenterol 94 (1999) 2246-2250
7. Tangkijvanich P., Thong-ngam D., Mahachai V., Kladchareon N., Suwangool P., and Kullavanijaya P. Long-term effect of interferon therapy on incidence of cirrhosis and hepatocellular carcinoma in Thai patients with chronic hepatitis B. Southeast Asian J Trop Med Public Health 32 (2001) 452-458
8. Papatheodoridis G.V., Manesis E., and Hadziyannis S.J. The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B. J Hepatol 34 (2001) 306-313
9. van Zonneveld M., Honkoop P., Hansen B.E., Niesters H.G., Murad S.D., de Man R.A., et al. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology 39 (2004) 804-810
10. Janssen H.L., van Zonneveld M., Senturk H., Zeuzem S., Akarca U.S., Cakaloglu Y., et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 365 (2005) 123-129
11. Baltayiannis G., Katsanos K., Karayiannis P., and Tsianos E.V. Interferon-alpha therapy in HBeAg-negative chronic hepatitis B: a long-term prospective study from north-western Greece. Aliment Pharmacol Ther 24 (2009) 525-533
12. Hui C.K., Leung N., Yuen S.T., Zhang H.Y., Leung K.W., Lu L., et al. Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase. Hepatology 46 (2007) 395-401
13. Hui C.K., Leung N., Shek T.W., Yao H., Lee W.K., Lai J.Y., et al. Sustained disease remission after spontaneous HBeAg seroconversion is associated with reduction in fibrosis progression in chronic hepatitis B Chinese patients. Hepatology 46 (2007) 690-698
14. Lin S.M., Yu M.L., Lee C.M., Chien R.N., Sheen I.S., Chu C.M., et al. Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol 46 (2007) 45-52
15. Poynard T., Ngo Y., Marcellin P., Hadziyannis S., Ratziu V., and Benhamou Y. Impact of adefovirdipivoxil on liver fibrosis and activity assessed with biochemical markers (FibroTest-ActiTest) in patients infected by Hepatitis B Virus. J Viral Hepat 16 (2009) 203-213
16. Moucari R., Korevaar A., Lada O., Martinot-Peignoux M., Boyer N., Mackiewicz V., et al. High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study. J Hepatol 50 (2009) 1084-1092
17. Yang Y.F., Zhao W., Zhong Y.D., Xia H.M., Shen L., and Zhang N. Interferon therapy in chronic hepatitis B reduces progression to cirrhosis and hepatocellular carcinoma: a meta-analysis. J Viral Hepat 16 (2009) 265-271
18. Rudin D., Shah S.M., Kiss A., Wetz R.V., and Sottile V.M. Interferon and lamivudine vs. interferon for hepatitis B e antigen-positive hepatitis B treatment: meta-analysis of randomized controlled trials. Liver Int 27 (2007) 1185-1193
19. Rudin D. Lamivudine and interferon versus lamivudine monotherapy for HBeAg-positive hepatitis B treatment: a meta-analysis of randomized, controlled trials. Adv Ther 24 (2007) 784-795
20. Benvegnù L., Chemello L., Noventa F., Fattovich G., Pontisso P., and Alberti A. Retrospective analysis of the effect of interferon therapy on the clinical outcome of patients with viral cirrhosis. Cancer 83 (1998) 901-909
21. Chan H.L., Leung N.W., Hui A.Y., Wong V.W., Liew C.T., Chim A.M., et al. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone. Ann Intern Med 142 (2005) 240-250
22. Farci P., Roskams T., Chessa L., Peddis G., Mazzoleni A.P., Scioscia R., et al. Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis. Gastroenterology 126 (2004) 1740-1749
23. Ikeda K., Saitoh S., Suzuki Y., Kobayashi M., Tsubota A., Fukuda M., et al. Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus: a pilot study. Cancer 82 (1998) 827-835
24. International Interferon-alpha Hepatocellular Carcinoma Study Group. Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. Lancet 351 (1998) 1535-1539
25. Lau G.K., Piratvisuth T., Luo K.X., Marcellin P., Thongsawat S., Cooksley G., et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 352 (2005) 2682-2695
26. Lin S.M., Tai D.I., Chien R.N., Sheen I.S., Chu C.M., and Liaw Y.F. Comparison of long-term effects of lymphoblastoid interferon alpha and recombinant interferon alpha-2a therapy in patients with chronic hepatitis B. J Viral Hepat 11 (2004) 349-357
27. Mazzella G., Accogli E., Sottili S., Festi D., Orsini M., Salzetta A., et al. Alpha interferon treatment may prevent hepatocellular carcinoma in HCV related liver cirrhosis. J Hepatol 24 (1996) 141-147
28. Lin S.M., Sheen I.S., Chien R.N., Chu C.M., and Liaw Y.F. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 29 (1999) 971-975
29. Yuen M.F., Hui C.K., Cheng C.C., Wu C.H., Lai Y.P., and Lai C.L. Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: the effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications. Hepatology 34 (2001) 139-145
30. Buster E.H., Hansen B.E., Buti M., Delwaide J., Niederau C., Michielsen P.P., et al. Peginterferon alpha-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosis. Hepatology 46 (2007) 388-394
31. Poynard T., Muntenau M., Morra R., Ngo Y., Imbert-Bismut F., Thabut D., et al. Methodological aspects for the interpretation of liver fibrosis non-invasive biomarkers: a 2008 update. Gastroenterol Clin Biol 32 (2008) 8-21
32. Halfon P., Munteanu M., and Poynard T. FibroTest-ActiTest as a non-invasive marker of liver fibrosis. Gastroenterol Clin Biol 32 (2008) 22-38
33. Ngo Y., Benhamou Y., Thibault V., Ingiliz P., Munteanu M., Lebray P., et al. An accurate definition of the status of inactive hepatitis B virus carrier by a combination of biomarkers (Fibrotest-Actitest) and viral load. PLoS One 3 (2008) e2573
34. Tsertsvadze T., Dolmazashvili E., Abutidze A., Sharvadze L., and Karchava M. Assessment of liver fibrosis and cirrhosis by transient elastography among patients with chronic HBV and HCV infection in Georgia. Georgian Med News 165 (2008) 38-42
35. Poynard T., Ingiliz P., Elkrief L., Munteanu M., Lebray P., Morra R., et al. Concordance in a world without a gold standard: A new non-invasive methodology for improving accuracy of fibrosis markers. PLoS One 3 (2008) e3857
36. Marcellin P., Ziol M., Bedossa P., Douvin C., Poupon R., de Lédinghen V., et al. Non-invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B. Liver Int 29 (2009) 242-247